All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
SRF231 is granted orphan designation status for the treatment of multiple myeloma
Bookmark this article
On 30 July 2018, the US Food and Drug Administration (FDA) included SRF231 (anti-CD47) among the list of orphan drugs to be used for treating multiple myeloma (MM) patients (pts).
SRF231 is a fully humanized monoclonal antibody, which targets the transmembrane protein CD47. Although CD47 is found at very low levels in most normal cell types, it is highly expressed by many different types of tumor cells, including myeloma cells. CD47 normally binds to the Signal Regulatory Protein Alpha (SIRPA), preventing cell phagocytosis. SRF231 binding to CD47 inhibits the link between CD47 and SIRPA, promoting phagocytosis and removal of myeloma cells.
Currently, the safety and maximum tolerated dose of SFR231 are being examined in a phase I clinical trial in patients with advanced solid and hematologic cancers.
SRF231’s orphan drug designation will support further investigations carried out by the drug research company Surface Oncology on the treating potential of this drug for MM pts.
- FDA Orphan Drug Designation and Approvals
- Rare DR (Rare Disease Report) online. Multiple Myeloma Treatment, SRF231, Receives Orphan Drug Designation by FDA. https://www.raredr.com/news/multiple-myeloma-treatment-srf231-receives-orphan-drug-designation-by-fda. [Assessed July 31 2018].
Your opinion matters
1 vote - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox